Team

Paolo has 25+ year of experience in the life science sector. He brings extensive experience in R&D and Commercialization in the Pharma Industry. Paolo was the first President of GSK Oncology, and, in eight years, he brought to cancer patients seven new medicines, focusing on precision medicine. Under his leadership, the GSK oncology franchise generated important value and it was sold to Novartis in 2014 for 14 b USD. In Lilly, he was responsible of the development of Alimta (NSCLC) with peak sales of 2 b+ USD. Currently, Paolo is the CEO of GammaDelta Therapeutics a company he started in 2017 and, in 5 years, he led the development of the allogeneic cell therapy of Vδ1 gamma delta T cells and the initiation of the clinical trial using (for the first time) the subtype Vδ1 of gamma delta T cells. Takeda in October 2021 exercised the option to acquire Gamma Delta Therapeutics. Paolo was professor of Pulmonary Medicine at the University of Pisa, and he has been the author of more than 300 publications. He is a member of the Board for Psioxus Therapeutics and Genmab Therapeutics where he is also the Chairman of the Scientific Committee.